Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1993;2(4):279–285. doi: 10.1155/S0962935193000389

Attenuation of amiodarone induced lung fibrosis and phospholipidosis in hamsters, by treatment with the platelet activating factor receptor antagonist, WEB 2086

S N Giri 1,✉, D M Hyde 2, D R Haynam 1, M Casias 1
PMCID: PMC2365411  PMID: 18475534

Abstract

Therapeutic use of amiodarone (AMD), a Class III antiarrhythmic drug is complicated by the development of lung fibrosis (LF) and phospholipidosis (PL). In the present study, the effectiveness of a PAF antagonist, WEB 2086, against AMD induced LF and PL has been tested in hamsters. The animals were randomly divided into four groups: (1) saline + H2O; (2) WEB + H2O; (3) saline + AMD; and (4) WEB + AMD. Saline or WEB (10 mg/kg i.p.) was given 2 days prior to intratracheal instillation of water or AMD (1.5 μmol/0.25 ml/100 g BW) and thereafter daily throughout the study. Twenty-eight days after intratracheal instillation, the animals were killed and the lungs processed for various assays. The amount of lung hydroxyproline, an index of LF, in saline + H2O, WEB + H2O, saline + AMD, and WEB + AMD groups were 959 ± 46, 1035 ± 51, 1605 ± 85 and 1374 ± 69 μg/lung, respectively. Total lung PL, an index of phospholipidosis, in the corresponding groups were 8.4 ± 0.4, 8.3 ± 0.3, 11.7 ± 0.3 and 9.9 μg/lung. Lung malondialdehyde, an index of lipid peroxidation and superoxide dismutase activity in saline + H2O WEB + H2O, saline + AMD, and WEB + AMD were 93.0 ± 4.3, 93.0 ± 2.7, 138.9 ± 6.0 and 109.0 ± 3.8 nmol/lung and 359.7 ± 13.9, 394.0 ± 22.8, 497.5 ± 19.7 and 425.5 ± 4.9 units/lung, respectively. Administration of AMD alone caused significant increases in all the above indexes of lung toxicity, and treatment with WEB 2086 minimized the AMD induced toxicity as reflected by significant decreases in these indexes. Histopathological studies revealed a marked reduction in the extent and severity of lung lesions in the WEB + AMD group compared with the saline + AMD group. Treatment with WEB 2086 also reduced the acute mortality from 35% in saline + AMD group to 22% in WEB + AMD group. It was concluded that PAF is involved in the AMD induced lung fibrosis and phospholipidosis and that the PAF receptor antagonist may, therefore, be potentially useful in reducing AMD induced lung toxicity.

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AMES B. N., DUBIN D. T. The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid. J Biol Chem. 1960 Mar;235:769–775. [PubMed] [Google Scholar]
  2. Akoun G. M., Cadranel J. L., Blanchette G., Milleron B. J., Mayaud C. M. Bronchoalveolar lavage cell data in amiodarone-associated pneumonitis. Evaluation in 22 patients. Chest. 1991 May;99(5):1177–1182. doi: 10.1378/chest.99.5.1177. [DOI] [PubMed] [Google Scholar]
  3. BLIGH E. G., DYER W. J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 Aug;37(8):911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  4. Cantor J. O., Osman M., Cerreta J. M., Suarez R., Mandl I., Turino G. M. Amiodarone-induced pulmonary fibrosis in hamsters. Exp Lung Res. 1984;6(1):1–10. doi: 10.3109/01902148409087891. [DOI] [PubMed] [Google Scholar]
  5. Caramelo C., Fernández-Gallardo S., Santos J. C., Iñarrea P., Sánchez-Crespo M., López-Novoa J. M., Hernando L. Increased levels of platelet-activating factor in blood from patients with cirrhosis of the liver. Eur J Clin Invest. 1987 Feb;17(1):7–11. doi: 10.1111/j.1365-2362.1987.tb01218.x. [DOI] [PubMed] [Google Scholar]
  6. Chandler D. B., Giri S. N. Changes in plasma concentrations of prostaglandins and plasma angiotensin-converting enzyme during bleomycin-induced lung fibrosis in hamsters. Am Rev Respir Dis. 1983 Jul;128(1):71–76. doi: 10.1164/arrd.1983.128.1.71. [DOI] [PubMed] [Google Scholar]
  7. Chandrakasan G., Bhatnagar R. S. Stimulation of collagen synthesis in fibroblast cultures by superoxide. Cell Mol Biol. 1991;37(7):751–755. [PubMed] [Google Scholar]
  8. Chung K. F. Platelet-activating factor in inflammation and pulmonary disorders. Clin Sci (Lond) 1992 Aug;83(2):127–138. doi: 10.1042/cs0830127. [DOI] [PubMed] [Google Scholar]
  9. Daniels J. M., Brien J. F., Massey T. E. Pulmonary fibrosis induced in the hamster by amiodarone and desethylamiodarone. Toxicol Appl Pharmacol. 1989 Sep 1;100(2):350–359. doi: 10.1016/0041-008x(89)90321-9. [DOI] [PubMed] [Google Scholar]
  10. Giri S. N., Chen Z. L., Younker W. R., Schiedt M. J. Effects of intratracheal administration of bleomycin on GSH-shuttle enzymes, catalase, lipid peroxidation, and collagen content in the lungs of hamsters. Toxicol Appl Pharmacol. 1983 Oct;71(1):132–141. doi: 10.1016/0041-008x(83)90052-2. [DOI] [PubMed] [Google Scholar]
  11. Giri S. N., Misra H. P., Chandler D. B., Chen Z. L. Increases in lung prolyl hydroxylase and superoxide dismutase activities during bleomycin-induced lung fibrosis in hamsters. Exp Mol Pathol. 1983 Dec;39(3):317–326. doi: 10.1016/0014-4800(83)90060-6. [DOI] [PubMed] [Google Scholar]
  12. Giri S. N., Nakashima J. M., Curry D. L. Effects of intratracheal administration of bleomycin or saline in pair-fed and control-fed hamsters on daily food intake and on plasma levels of glucose, cortisol, and insulin, and lung levels of calmodulin, calcium, and collagen. Exp Mol Pathol. 1985 Apr;42(2):206–219. doi: 10.1016/0014-4800(85)90028-0. [DOI] [PubMed] [Google Scholar]
  13. Giri S. N., Sanford D. A., Jr, Robison T. W., Tyler N. K. Impairment in coupled beta-adrenergic receptor and adenylate cyclase system during bleomycin-induced lung fibrosis in hamsters. Exp Lung Res. 1987;13(4):401–416. doi: 10.3109/01902148709069601. [DOI] [PubMed] [Google Scholar]
  14. Giri S. N., Witt T. C. Effects of intratracheal administration of bleomycin on prostaglandins and thromboxane-B2 and collagen levels of the lung in hamsters. Exp Lung Res. 1985;9(1-2):119–133. doi: 10.3109/01902148509061532. [DOI] [PubMed] [Google Scholar]
  15. Heger J. J., Prystowsky E. N., Zipes D. P. Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation. Am Heart J. 1983 Oct;106(4 Pt 2):887–894. doi: 10.1016/0002-8703(83)90012-1. [DOI] [PubMed] [Google Scholar]
  16. Israël-Biet D., Venet A., Caubarrère I., Bonan G., Danel C., Chrétien J., Hance A. J. Bronchoalveolar lavage in amiodarone pneumonitis. Cellular abnormalities and their relevance to pathogenesis. Chest. 1987 Feb;91(2):214–221. doi: 10.1378/chest.91.2.214. [DOI] [PubMed] [Google Scholar]
  17. Karlinsky J. B., Goldstein R. H. Fibrotic lung disease--a perspective. J Lab Clin Med. 1980 Dec;96(6):939–942. [PubMed] [Google Scholar]
  18. Kelley J., Newman R. A., Evans J. N. Bleomycin-induced pulmonary fibrosis in the rat. Prevention with an inhibitor of collagen synthesis. J Lab Clin Med. 1980 Dec;96(6):954–964. [PubMed] [Google Scholar]
  19. Kennedy T. P., Gordon G. B., Paky A., McShane A., Adkinson N. F., Jr, Peters S. P., Friday K., Jackman W., Sciuto A. M., Gurtner G. H. Amiodarone causes acute oxidant lung injury in ventilated and perfused rabbit lungs. J Cardiovasc Pharmacol. 1988 Jul;12(1):23–36. doi: 10.1097/00005344-198807000-00004. [DOI] [PubMed] [Google Scholar]
  20. Leak D., Eydt J. N. Control of refractory cardiac arrhythmias with amiodarone. Arch Intern Med. 1979 Apr;139(4):425–428. [PubMed] [Google Scholar]
  21. Lewis M. S., Whatley R. E., Cain P., McIntyre T. M., Prescott S. M., Zimmerman G. A. Hydrogen peroxide stimulates the synthesis of platelet-activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion. J Clin Invest. 1988 Dec;82(6):2045–2055. doi: 10.1172/JCI113825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Li A. S., Chignell C. F. Spectroscopic studies of cutaneous photosensitizing agents--IX. A spin trapping study of the photolysis of amiodarone and desethylamiodarone. Photochem Photobiol. 1987 Feb;45(2):191–197. doi: 10.1111/j.1751-1097.1987.tb05363.x. [DOI] [PubMed] [Google Scholar]
  23. Lin A. H., Morton D. R., Gorman R. R. Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes. J Clin Invest. 1982 Nov;70(5):1058–1065. doi: 10.1172/JCI110693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Marchlinski F. E., Gansler T. S., Waxman H. L., Josephson M. E. Amiodarone pulmonary toxicity. Ann Intern Med. 1982 Dec;97(6):839–845. doi: 10.7326/0003-4819-97-6-839. [DOI] [PubMed] [Google Scholar]
  25. Martin W. J., 2nd, Standing J. E. Amiodarone pulmonary toxicity: biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects. J Pharmacol Exp Ther. 1988 Feb;244(2):774–779. [PubMed] [Google Scholar]
  26. Misra H. P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972 May 25;247(10):3170–3175. [PubMed] [Google Scholar]
  27. Nakashima J. M., Hyde D. M., Giri S. N. Epithelial injury, inflammation, and repair in the hamster lung following intratracheal instillation of enzyme-generated oxidants. Exp Lung Res. 1991 May-Jun;17(3):569–587. doi: 10.3109/01902149109062866. [DOI] [PubMed] [Google Scholar]
  28. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979 Jun;95(2):351–358. doi: 10.1016/0003-2697(79)90738-3. [DOI] [PubMed] [Google Scholar]
  29. Peplow P. V., Mikhailidis D. P. Platelet-activating factor (PAF) and its relation to prostaglandins, leukotrienes and other aspects of arachidonate metabolism. Prostaglandins Leukot Essent Fatty Acids. 1990 Oct;41(2):71–82. doi: 10.1016/0952-3278(90)90057-r. [DOI] [PubMed] [Google Scholar]
  30. Primeau R., Agha A., Giorgi C., Shenasa M., Nadeau R. Long term efficacy and toxicity of amiodarone in the treatment of refractory cardiac arrhythmias. Can J Cardiol. 1989 Mar;5(2):98–104. [PubMed] [Google Scholar]
  31. Prockop D. J., Kivirikko K. I., Tuderman L., Guzman N. A. The biosynthesis of collagen and its disorders (first of two parts). N Engl J Med. 1979 Jul 5;301(1):13–23. doi: 10.1056/NEJM197907053010104. [DOI] [PubMed] [Google Scholar]
  32. Reasor M. J., Ogle C. L., Walker E. R., Kacew S. Amiodarone-induced phospholipidosis in rat alveolar macrophages. Am Rev Respir Dis. 1988 Mar;137(3):510–518. doi: 10.1164/ajrccm/137.3.510. [DOI] [PubMed] [Google Scholar]
  33. Rodriguez-Barbero A., Bosque E., Rivas-Cabaero L., Arévalo M., López-Novoa J. M. Effect of platelet activating factor antagonist treatment on gentamicin nephrotoxicity. Mediators Inflamm. 1992;1(1):23–26. doi: 10.1155/S096293519200005X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rosenbaum M. B., Chiale P. A., Halpern M. S., Nau G. J., Przybylski J., Levi R. J., Lázzari J. O., Elizari M. V. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934–944. doi: 10.1016/0002-9149(76)90807-9. [DOI] [PubMed] [Google Scholar]
  35. Sandron D., Israel-Biet D., Venet A., Chretien J. Immunoglobulin abnormalities in bronchoalveolar lavage specimens from amiodarone-treated subjects. Chest. 1986 Apr;89(4):617–618. doi: 10.1378/chest.89.4.617b. [DOI] [PubMed] [Google Scholar]
  36. Schaberg T., Haller H., Lode H. Evidence for a platelet-activating factor receptor on human alveolar macrophages. Biochem Biophys Res Commun. 1991 Jun 14;177(2):704–710. doi: 10.1016/0006-291x(91)91845-4. [DOI] [PubMed] [Google Scholar]
  37. Singh B. N. Amiodarone: historical development and pharmacologic profile. Am Heart J. 1983 Oct;106(4 Pt 2):788–797. doi: 10.1016/0002-8703(83)90002-9. [DOI] [PubMed] [Google Scholar]
  38. Sobol S. M., Rakita L. Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation. 1982 Apr;65(4):819–824. doi: 10.1161/01.cir.65.4.819. [DOI] [PubMed] [Google Scholar]
  39. Stenmark K. R., Eyzaguirre M., Westcott J. Y., Henson P. M., Murphy R. C. Potential role of eicosanoids and PAF in the pathophysiology of bronchopulmonary dysplasia. Am Rev Respir Dis. 1987 Sep;136(3):770–772. doi: 10.1164/ajrccm/136.3.770. [DOI] [PubMed] [Google Scholar]
  40. Suzawa H., Kikuchi S., Arai N., Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol. 1992 Oct;60(2):91–96. doi: 10.1254/jjp.60.91. [DOI] [PubMed] [Google Scholar]
  41. WOESSNER J. F., Jr The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961 May;93:440–447. doi: 10.1016/0003-9861(61)90291-0. [DOI] [PubMed] [Google Scholar]
  42. Wang Q., Giri S. N., Hyde D. M. Characterization of a phospholipase A2 in hamster lung and in vitro and in vivo effects of bleomycin on this enzyme. Prostaglandins Leukot Essent Fatty Acids. 1989 May;36(2):85–92. doi: 10.1016/0952-3278(89)90023-9. [DOI] [PubMed] [Google Scholar]
  43. Wang Q., Hollinger M. A., Giri S. N. Attenuation of amiodarone-induced lung fibrosis and phospholipidosis in hamsters by taurine and/or niacin treatment. J Pharmacol Exp Ther. 1992 Jul;262(1):127–132. [PubMed] [Google Scholar]
  44. Wardlaw A. J., Moqbel R., Cromwell O., Kay A. B. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest. 1986 Dec;78(6):1701–1706. doi: 10.1172/JCI112765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zhou W., Chao W., Levine B. A., Olson M. S. Role of platelet-activating factor in hepatic responses after bile duct ligation in rats. Am J Physiol. 1992 Nov;263(5 Pt 1):G587–G592. doi: 10.1152/ajpgi.1992.263.5.G587. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES